RTW INVESTMENTS, LP
Institutional investor · Portfolio as of Q3 2025
Top Holdings74 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
MADRIGAL PHARMACEUTICALS INC | 2M | $914.4M | 11.3% | $265.36 | +66.98% | 10 qtrssince 2023-Q2 | Unchanged 0 |
ARGENX SE - ADR | 673,497 | $496.7M | 6.1% | $356.02 | +107.17% | 27 qtrssince 2019-Q1 | Unchanged 0 |
| 11.4M | $495.5M | 6.1% | $28.95 | — | 22 qtrssince 2020-Q2 | Increased 71 | |
PTC THERAPEUTICS INC | 7.7M | $475.4M | 5.9% | $43.73 | +38.69% | 27 qtrssince 2019-Q1 | Unchanged 0 |
INSMED INC | 3.1M | $444.2M | 5.5% | $45.51 | +211.27% | 10 qtrssince 2023-Q2 | Unchanged 0 |
PROTAGONIST THERAPEUTICS INC | 5.8M | $382.4M | 4.7% | $24.36 | +167.46% | 25 qtrssince 2019-Q3 | Unchanged 0 |
NATERA INC | 2M | $321.9M | 4.0% | $42.13 | +287.12% | 25 qtrssince 2019-Q3 | Decreased 0 |
AKERO THERAPEUTICS INC | 5.5M | $260.1M | 3.2% | $26.19 | — | 8 qtrssince 2023-Q4 | Unchanged 0 |
uniQure N.V. | 4.4M | $258.3M | 3.2% | $13.52 | +339.38% | 5 qtrssince 2024-Q3 | Decreased 0 |
PENUMBRA INC | 866,499 | $219.5M | 2.7% | $249.62 | +0.81% | 17 qtrssince 2021-Q3 | Increased 53 |
RadNet, Inc. | 2.8M | $214.6M | 2.6% | $49.74 | +50.17% | 8 qtrssince 2023-Q4 | Increased 55 |
MERUS N V | 2M | $190.7M | 2.3% | $34.06 | — | 10 qtrssince 2023-Q2 | Decreased 0 |
TARSUS PHARMACEUTICALS INC | 3.2M | $188.8M | 2.3% | $33.75 | +72.11% | 20 qtrssince 2020-Q4 | Increased 53 |
STRYKER CORP | 490,000 | $181.1M | 2.2% | $356.27 | +3.33% | 5 qtrssince 2024-Q3 | Decreased 0 |
IMMUNOCORE HLDGS PLC | 4.9M | $176.9M | 2.2% | $43.05 | -20.23% | 19 qtrssince 2021-Q1 | Unchanged 0 |
ACADIA Pharmaceuticals Inc. | 7.1M | $152.5M | 1.9% | $18.54 | +15.00% | 14 qtrssince 2022-Q2 | Decreased 0 |
CYTOKINETICS INC | 2.7M | $149.6M | 1.8% | $28.96 | +89.77% | 21 qtrssince 2020-Q3 | Unchanged 0 |
NEUROCRINE BIOSCIENCES INC | 1.1M | $149.1M | 1.8% | $125.42 | +11.84% | 2 qtrssince 2025-Q2 | Unchanged 0 |
AXSOME THERAPEUTICS INC | 1.1M | $135.9M | 1.7% | $62.01 | +89.67% | 27 qtrssince 2019-Q1 | Decreased 0 |
STOKE THERAPEUTICS INC | 5.1M | $120.4M | 1.5% | $23.04 | +7.34% | 26 qtrssince 2019-Q2 | Unchanged 0 |
RTW INVESTMENTS, LP manages $8.1B across 74 positions as of Q3 2025. Top holdings: MDGL (11.3%), ARGX (6.1%), RNAM (6.1%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3/5.0.
Active quarter - 10 new positions, 9 exits, 17 increased. Top move: RNAM (INCREASED, conviction 71). Portfolio: $8.1B across 74 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer